News

Strides Pharma Science share price gained in the opening trade on April 30 after the company's US-based arm acquires 4 ANDAs for US market from Nostrum Laboratories Inc.

At 09:24am, Strides Pharma Science was quoting at Rs 657.40, up Rs 4.85, or 0.74 percent, on the BSE.

Strides Pharma Inc., a step-down wholly owned subsidiary of the company in the US, has acquired four approved ANDAs for the US market from Nostrum Laboratories, Inc., USA.

The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs (Urinary Tract Infections), Pain Management, Allergy Symptoms and Attention Deficit Disorder (ADD/ ADHD) and Narcolepsy, company said.

The total consideration for the said ANDAs acquisition is USD 2.075 million (~ Rs 176 million).

Two (out of the four) ANDAs acquired are commercial products and is expected to be launched within 12 months.

With access to these products, Strides will expand its portfolio of niche and difficult to manufacture products.

Catch all the market action on our live blog

The share touched a 52-week high of Rs 1,675.25 and a 52-week low of Rs 530.70 on 17 October, 2024 and 27 January, 2025, respectively.

Currently, the stock is trading 60.76 percent below its 52-week high and 23.87 percent above its 52-week low.

The market capitalisation stands at Rs 6,058.78 crore.

The share price shed more than 56 percent in the last six months.

Discover the latest Business News, Budget 2025 News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Sensex Today Jammu Kashmir News Live DC vs KKR Live Score Canada Election Results Q4 Results 2025 Live Ather Energy IPO GMP JKBOSE 10th Result 2025 TS SSC Results 2025 NEET Admit Card 2025 IPL Points Table 2025

Business Markets Stocks India News City News Economy Mutual Funds Personal Finance IPO News Startups

Home Currencies Commodities Pre-Market IPO Global Market Bonds

Home Loans up to 50 Lakhs Credit Cards Lifetime Free Finance TrackerNew Fixed Deposits Fixed Deposit Comparison Fixed Income

Home MC 30 Top Ranked Funds ETFs Mutual Fund Screener

Income Tax Calculator EMI Calculator Retirement Planning Gratuity Calculator

Stock Markets

News18 Firstpost CNBC TV18 News18 Hindi Cricketnext Overdrive Topper Learning

About Us Contact Us Advisory Alert Advertise with Us SupportDisclaimer Privacy Policy Cookie Policy Terms & Conditions Financial Terms (Glossary) Sitemap Investors

You are already a Moneycontrol Pro user.